Vitamin D receptor gene polymorphisms and the risk for female reproductive cancers: A meta-analysis
Maturitas, Volume 81, Issue 2, June 2015, Pages 256–265
Myung-Jin Mun a, b, Tae-Hee Kim c heeobgy@naver.com Ji-Young Hwang d, Won-Cheoul Jang a
a Department of Chemistry, School of Natural Science, Dankook University, Cheonan 330-714, Republic of Korea
b Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 330-714, Republic of Korea
c Department of Obstetrics and Gynecology, Soonchunhyang University College of Medicine, Bucheon 420-767, Republic of Korea
d Department of Biomedical Engineering, Korea University College of Health Science, Seoul 136-713, Republic of Korea
Highlights
- The FokI polymorphism was related to increased risks for breast and ovarian cancers.
- The BsmI polymorphism was associated with a decreased risk for developing cancers.
- We suggest monitoring VDR gene polymorphisms as potential biomarkers.
Folki gene error is again found to be related to increased rates of breast and ovarian cancers
Many other studies have found similar increased risk of a variety of cancers due to genes
The errors slightly reduce the Vitamin D Receptor (VDR)
Unfortunately the effect of VDR modification cannot be detected with vitamin D tests
The reduction of reception of the vitamin D happens after it has left the bloodstream
However, people with these errors can compensate by taking slightly more vitamin D
See also VitaminDWiki
- Breast Cancer rate reduced 72 percent by vitamin D gene polymorphism CYP24A1 – Nov 2014
- Genes and Vitamin D - Malacards
- Receptor = VDR category listing has
530 items along with related searches - Health outcomes of vitamin D. Parts I (VDR) and II – 2014
- Diseases, Vitamin D Receptor and other genes – June 2014
- Response to 1000 IU of vitamin D varies by about 4 percent due to gene variants – RCT July 2014
- Melanoma risk 2X to 4X higher if Vitamin D receptor genes had morphed – March 2014
- Vitamin D receptor polymorphisms are risk factors for various cancers – meta-analysis Jan 2014
Pages listed in BOTH Breast Cancer AND Genetics
- Suppression of CYP24A1 gene got more Vitamin D to cells to fight Breast Cancer – March 2023
- DNA analysis of genes (Polygenic risk) shows increased risk of 9 health problems (all 9 fought by Vitamin D) – Feb 2024
- Breast Cancer chemotherapy improved if able to suppress a vitamin D gene (CYP24A1) – May 2023
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Many Ashkenazi Jewish diseases associated with low vitamin D or poor Vit D genes
- Breast Cancer far more likely in the sister having poor Vitamin D binding protein or poor CYP2R1 gene – March 2018
- Breast Cancer rate reduced 72 percent by vitamin D gene polymorphism CYP24A1 – Nov 2014
- Genes may account for some of AA Breast Cancer – April 2012
- Breast cancer and Vitamin D receptors, CP27B1, and CYP24A1 – Sept 2010
- Genes breast cancer and vitamin D receptor - Sept 2010
Pages listed in BOTH Breast Cancer AND Vitamin D Receptor
- Breast Cancer prevented in 5 ways via the Vitamin D Receptor – Oct 2024
- Poor Vitamin D Receptor does not increase the risk of Breast Cancer (but the opposite is true) – umbrella meta-analysis Sept 2024
- An activated Vitamin D Receptor fights Autoimmune Diseases, Infections, Cancers, etc. – Dec 2023
- Breast Cancer risk reduced if consume butyrate - Dec 2023
- Breast cancer spreads to bone if poor vitamin D Receptor (no surprise) – Oct 2022
- Some breast cancers may be treated RNA changes caused by Vitamin D – March 2022
- Breast Cancer, Vitamin D, and genes – Welsh Nov 2021
- After lactation Vitamin D levels are low, increased risk of Breast Cancer, vitamin D should decrease risk – Aug 2021
- Breasts process Vitamin D and change gene activation, might prevent breast cancer if given more Vit. D – July 2021
- Breast cancer associated with Vitamin D Receptor (14th study) – Oct 2019
- After breast cancer treatment 4,000 IU of Vitamin D was not enough to help if have poor Vitamin D receptor – June 2019
- Breast Cancer death 1.8 X more likely if poor Vitamin D Receptor – April 2019
- Breast Cancer and Vitamin D review – March 2018
- Women with Breast Cancer were 16.9 times more likely to have a poor Vitamin D Receptor – Jan 2019
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Two chemicals increase the Vitamin D receptor and decrease the growth of breast cancer cells in the lab - March 2018
- Breast Cancer reduces receptor and thus blocks Vitamin D to the cells – several studies
- Vitamin D receptor as a target for breast cancer therapy (abstract only) – Feb 2017
- Breast Cancer was 4.6 times more likely if have a poor Vitamin D Receptor – Dec 2016
- Increased Breast Cancer metastasis if low vitamin D or poor VDR – Feb 2016
- Increased risk of some female cancers if low vitamin D (due to genes) – meta-analysis June 2015
- Vitamin D receptor in breasts and breast cancer vary with race – March 2013
- Breast Cancer incidence change by 40 percent with vitamin D receptor genes – Oct 2012
- Genes breast cancer and vitamin D receptor - Sept 2010
Vitamin D receptor (VDR) gene polymorphisms and the risks for various breast and ovarian cancers have been reported in many epidemiological studies. However, the associations between VDR gene polymorphisms and the risk for each type of cancer are unclear. The aim of this meta-analysis was to evaluate the associations between VDR gene polymorphisms and female reproductive cancers. A systematic review was performed with the PubMed Science Direct, Scopus, and Google Scholar databases up to April 2014 using the search terms “vitamin D receptor or VDR” and “variant or polymorphism or SNP” with terms for breast, ovarian, cervical, endometrial, uterine, and vaginal cancers. A meta-analysis with the pooled odds ratios and 95% confidence intervals was carried out to assess the associations between VDR polymorphisms (Cdx-2, FokI, BsmI, ApaI, and TaqI) and the risks for reproductive cancers under the heterozygous, homozygous, dominant, and recessive models with fixed or random effects models.
Six ovarian cancer studies (13 individual studies involving 4107 cases and 6661 controls) and 29 breast cancer studies (38 individual studies involving 16,453 cases and 22,044 controls) were included in our meta-analysis.Our results indicate that the FokI polymorphism was related to increased risks for breast and ovarian cancers, whereas the BsmI polymorphism was associated with a decreased risk for developing these cancers. Our comprehensive meta-analysis indicated that the FokI and BsmI VDR gene polymorphisms may be significantly associated with gynecological cancers. We suggest monitoring VDR gene polymorphisms as potential biomarkers in patients with gynecological malignancy.
Abbreviations: VDR, vitamin D receptor; OR, odds ratio; CI, confidence interval; HWE, Hardy–Weinberg equilibrium
Publisher wants USD 36 for the PDF
Printer Friendly Follow this page for updates5149 visitors, last modified 10 Dec, 2016,